CONMED Corp (CNMD) stock
CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 14/3029% below fair value
$48.39−0.96 (-1.95%)
Close on Nov 17, 2026Market cap $1.44BP/E 20.0Yield 1.24%
Conmed r&d expenses
Research and development expenses are spending on new products and technology.
Conmed's R&D Expenses for the twelve months ending Sep 30, 2026 was $62.32M, up 15.1% year over year. For fiscal 2025 it was $55.88M, up 2.7% from the year before. Over ten years it grew 7.4% a year on average. The highest annual figure on record is $55.88M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.88M | +2.7% |
| FY2024 | Dec 31, 2024 | $54.43M | +3.5% |
| FY2023 | Dec 31, 2023 | $52.60M | +11.6% |
| FY2022 | Dec 31, 2022 | $47.15M | +8.2% |
| FY2021 | Dec 31, 2021 | $43.57M | +7.6% |
| FY2020 | Dec 31, 2020 | $40.47M | -11.0% |
| FY2019 | Dec 31, 2019 | $45.46M | +7.8% |
| FY2018 | Dec 31, 2018 | $42.19M | +30.6% |
| FY2017 | Dec 31, 2017 | $32.31M | +0.2% |
| FY2016 | Dec 31, 2016 | $32.25M | +17.6% |
| FY2015 | Dec 31, 2015 | $27.44M | -1.2% |
| FY2014 | Dec 31, 2014 | $27.78M | +7.5% |
| FY2013 | Dec 31, 2013 | $25.83M | -8.4% |
| FY2012 | Dec 31, 2012 | $28.21M | -1.5% |
| FY2011 | Dec 31, 2011 | $28.65M | -3.4% |
| FY2010 | Dec 31, 2010 | $29.65M | -6.9% |
| FY2009 | Dec 31, 2009 | $31.84M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.59M | +12.1% |
| Q2 FY2026 | Jun 30, 2026 | $15.50M | +9.6% |
| Q1 FY2026 | Mar 31, 2026 | $16.33M | +26.2% |
| Q4 FY2025 | Dec 31, 2025 | $14.90M | +13.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.90M | +2.5% |
| Q2 FY2025 | Jun 30, 2025 | $14.14M | +0.3% |
| Q1 FY2025 | Mar 31, 2025 | $12.95M | -4.8% |
| Q4 FY2024 | Dec 31, 2024 | $13.18M | -6.1% |
| Q3 FY2024 | Sep 30, 2024 | $13.56M | +8.8% |
| Q2 FY2024 | Jun 30, 2024 | $14.10M | +3.9% |
| Q1 FY2024 | Mar 31, 2024 | $13.59M | +8.4% |
| Q4 FY2023 | Dec 31, 2023 | $14.03M | +14.8% |
| Q3 FY2023 | Sep 30, 2023 | $12.46M | -2.4% |
| Q2 FY2023 | Jun 30, 2023 | $13.57M | +18.1% |
| Q1 FY2023 | Mar 31, 2023 | $12.54M | +17.5% |
| Q4 FY2022 | Dec 31, 2022 | $12.22M | +7.6% |
| Q3 FY2022 | Sep 30, 2022 | $12.77M | +17.6% |
| Q2 FY2022 | Jun 30, 2022 | $11.49M | +1.5% |
| Q1 FY2022 | Mar 31, 2022 | $10.67M | +6.4% |
| Q4 FY2021 | Dec 31, 2021 | $11.36M | -3.0% |
| Q3 FY2021 | Sep 30, 2021 | $10.86M | +9.3% |
| Q2 FY2021 | Jun 30, 2021 | $11.32M | +30.1% |
| Q1 FY2021 | Mar 31, 2021 | $10.03M | -0.9% |
| Q4 FY2020 | Dec 31, 2020 | $11.72M | -3.1% |
| Q3 FY2020 | Sep 30, 2020 | $9.94M | -9.5% |
| Q2 FY2020 | Jun 30, 2020 | $8.70M | -26.3% |
| Q1 FY2020 | Mar 31, 2020 | $10.12M | -4.3% |
| Q4 FY2019 | Dec 31, 2019 | $12.09M | +16.6% |
| Q3 FY2019 | Sep 30, 2019 | $10.99M | -22.2% |
| Q2 FY2019 | Jun 30, 2019 | $11.81M | +18.2% |
| Q1 FY2019 | Mar 31, 2019 | $10.58M | +37.1% |
| Q4 FY2018 | Dec 31, 2018 | $10.37M | +23.8% |
| Q3 FY2018 | Sep 30, 2018 | $14.12M | +70.8% |
| Q2 FY2018 | Jun 30, 2018 | $9.99M | +24.2% |
| Q1 FY2018 | Mar 31, 2018 | $7.71M | +1.2% |
| Q4 FY2017 | Dec 31, 2017 | $8.38M | +9.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.27M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.62M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.63M | – |
See a number that looks wrong?